Shift in Bisphosphonate Tx After 2008 Recommendations

Share this content:
Shift in Bisphosphonate Tx After 2008 Recommendations
Shift in Bisphosphonate Tx After 2008 Recommendations

THURSDAY, Feb. 9, 2017 (HealthDay News) -- In response to revised osteoporosis recommendations in 2008, there was a shift in age-related trends in oral bisphosphonate (BP) therapy initiation, according to a study published online Feb. 2 in the Journal of the American Geriatrics Society.

David R. Lee, M.D., M.B.A., from Kaiser Permanente Oakland in California, and colleagues conducted a retrospective study involving Kaiser Permanente Northern California female members aged ≥45 years who initiated BP therapy between 2004 and 2012. The cohort was stratified by early (2004 to 2007) and later (2009 to 2012) eras, with revised osteoporosis recommendations introduced in 2008.

The researchers found that 31 percent of the 72,026 women who initiated oral BP received a fracture diagnosis within the previous five years. Two distinct time trends were observed in initiation of oral BP: The proportions of women aged under 65 (34 to 37 percent) and aged 65 years and older (63 to 66 percent) were stable from 2004 to 2007; from 2008 to 2012, there was a decrease in the proportion of younger women (31 to 17 percent) and an increase in the proportion of older women (69 to 83 percent). These trends were similar among those with and without prior fracture.

"In summary, within Kaiser Permanente Northern California, we observed a substantial shift in BP treatment initiation that reflected changing practice in response to national guidelines and quality metrics," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; one author received payment for serving as an expert witness in litigation involving Fosamax.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »